Samsung enters agreement on manufacture of antibody cancer drug

Published: 19-Sep-2023
Manufacturing

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance

Samsung Biologics has announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. 

Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company’s latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea. 

This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply

- John Rim, President and CEO of Samsung Biologics

“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” said John Rim, President and CEO of Samsung Biologics. 

“This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity,” continued Rim. 

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering development and manufacturing solutions from cell line development to final aseptic fill/finish.

  • Companies:
  • Samsung Biologics
See more

You may also like

Manufacturing

Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant

Read more
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them

Trending Articles

  1. IMA Life and RheaVita team up to commercialise continuous biopharmaceutical freeze-drying tech The companies will work in tandem to develop and commercialise its continuous freeze-drying technology, allowing the rapid production of complex biopharmaceuticals
  2. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  3. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  4. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation
  5. Adragos Pharma enhances its sterile injectable production capabilities with new €13m ampoule filling line The novel line at the CDMO's Livron-sur-Drôme site in France will allow the company to manufacture more than 160 million ampoules for sterile injectables annually

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant

The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Manufacturing

Navigating biologics chemistry, manufacturing and controls with an innovative CDMO

Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Unearthing the potential of CDMO services to accelerate complex biologics development

The biologics landscape continues to transform in response to technological advancements and a growing understanding of molecular biology and biochemistry. As a result, an influx of both novel and complex therapeutics is entering the development pipeline, including bispecific antibodies (BsAbs), fusion proteins and antibody-drug conjugates (ADCs). However, these new moieties bring unique and potentially unfamiliar development and manufacturing difficulties
Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Manufacturing

Samsung Biologics commences construction on fifth plant

The company will invest over KRW 1.9 trillion in the new facility and break ground in the first half of this year
Manufacturing

Bioprocessing in the balance: part I

Dr Kevin Robinson recently caught up with Na Hye-jung, Head of Global Regulatory Affairs at Samsung Biologics, to pose the question: how do you solve the process optimisation equation of speed-to-market and cost efficiencies while maintaining a safe environment for both operators and end users?
Subscribe now